Brainstorm Cell Therapeutics Inc <BCLI.PK> expected to post a loss of 37 cents a share - Earnings Preview
Brainstorm Cell Therapeutics Inc BCLI.PK is expected to show no change in quarterly revenue when it reports results on August 14 for the period ending June 30 2025
LSEG's mean analyst estimate for Brainstorm Cell Therapeutics Inc is for a loss of 37 cents per share.
The one available analyst rating on the shares is "hold".
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Brainstorm Cell Therapeutics Inc is $19.76, about 96.8% above its last closing price of $0.64
This summary was machine generated August 8 at 17:48 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
Related Articles
Investing in Edge Computing
Edge computing complements the cloud by reducing latency, saving bandwidth, and enhancing privacy for real-time applications. Growth is fueled by IoT expansion, 5G rollout, AI integration, and enterprise digital transformation.
Fed Rate Cut Finally Arrives,Dollar Index: Negative Catalysts Largely Priced In,Euro Rally May Be Running Out of Steam
Tradingkey - The Federal Reserve lowered the target range for the federal funds rate by 25 basis points to 4.00%–4.25% late yesterday, as widely expected, and signaled two additional rate cuts this year.
September Global Central Bank Divergence: How Will U.S. Stocks and Forex Markets Move?
TradingKey - Despite the divergence in monetary policies among major global central banks in September (with the Federal Reserve cutting rates while the European Central Bank, Bank of England, and Bank of Japan maintain steady rates), we expect the policy directions of the Fed, ECB, and BoE to...
Bitcoin Price Forecast: Trends and Investment Outlook from 2025 to 2030
From $0.01 in 2009 to $120,000+ in 2025, Bitcoin has evolved from obscurity to a globally recognized financial asset. While institutions and governments increasingly embrace it, investors must remain vigilant against volatility, security risks, and scams.
ASML Q2 FY2025 Earnings Review: Strong Growth and High-NA EUV Breakthrough Shadowed by 2026 Uncertainty
ASML Holding N.V. (NASDAQ: ASML) released its Q2 FY2025 earnings on July 16, 2025, exceeding market expectations with robust net sales and net bookings, though the stock fell around 10% due to cautious guidance for 2026 amid geopolitical uncertainties.
